N

NewGLab Pharma Co Ltd
KOSDAQ:214870

Watchlist Manager
NewGLab Pharma Co Ltd
KOSDAQ:214870
Watchlist
Price: 6 915 KRW -27.44% Market Closed
Market Cap: 323.6B KRW
Have any thoughts about
NewGLab Pharma Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one NewGLab Pharma Co Ltd stock under the Base Case scenario is 84.39 KRW. Compared to the current market price of 6 915 KRW, NewGLab Pharma Co Ltd is Overvalued by 99%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
84.39 KRW
Overvaluation 99%
Intrinsic Value
Price
N
Base Case Scenario

Valuation History
NewGLab Pharma Co Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
NewGLab Pharma Co Ltd
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for NewGLab Pharma Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about NewGLab Pharma Co Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

6 915 KRW
-27.44%
-27.44%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

NewGLab Pharma Co Ltd
KR
Electrical Equipment
Market Cap
323.6B KRW
IPO
Oct 13, 2015
Employees
-
Korea
Market Cap
323.6B KRW
Industry
Electrical Equipment
IPO
Oct 13, 2015
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about NewGLab Pharma Co Ltd

Provide an overview of the primary business activities
of NewGLab Pharma Co Ltd.

What unique competitive advantages
does NewGLab Pharma Co Ltd hold over its rivals?

What risks and challenges
does NewGLab Pharma Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for NewGLab Pharma Co Ltd.

Provide P/S
for NewGLab Pharma Co Ltd.

Provide P/E
for NewGLab Pharma Co Ltd.

Provide P/OCF
for NewGLab Pharma Co Ltd.

Provide P/FCFE
for NewGLab Pharma Co Ltd.

Provide P/B
for NewGLab Pharma Co Ltd.

Provide EV/S
for NewGLab Pharma Co Ltd.

Provide EV/GP
for NewGLab Pharma Co Ltd.

Provide EV/EBITDA
for NewGLab Pharma Co Ltd.

Provide EV/EBIT
for NewGLab Pharma Co Ltd.

Provide EV/OCF
for NewGLab Pharma Co Ltd.

Provide EV/FCFF
for NewGLab Pharma Co Ltd.

Provide EV/IC
for NewGLab Pharma Co Ltd.

What are the Revenue projections
for NewGLab Pharma Co Ltd?

How accurate were the past Revenue estimates
for NewGLab Pharma Co Ltd?

What are the Net Income projections
for NewGLab Pharma Co Ltd?

How accurate were the past Net Income estimates
for NewGLab Pharma Co Ltd?

What are the EPS projections
for NewGLab Pharma Co Ltd?

How accurate were the past EPS estimates
for NewGLab Pharma Co Ltd?

What are the EBIT projections
for NewGLab Pharma Co Ltd?

How accurate were the past EBIT estimates
for NewGLab Pharma Co Ltd?

Compare the revenue forecasts
for NewGLab Pharma Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of NewGLab Pharma Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of NewGLab Pharma Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of NewGLab Pharma Co Ltd compared to its peers.

Compare the P/E ratios
of NewGLab Pharma Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing NewGLab Pharma Co Ltd with its peers.

Analyze the financial leverage
of NewGLab Pharma Co Ltd compared to its main competitors.

Show all profitability ratios
for NewGLab Pharma Co Ltd.

Provide ROE
for NewGLab Pharma Co Ltd.

Provide ROA
for NewGLab Pharma Co Ltd.

Provide ROIC
for NewGLab Pharma Co Ltd.

Provide ROCE
for NewGLab Pharma Co Ltd.

Provide Gross Margin
for NewGLab Pharma Co Ltd.

Provide Operating Margin
for NewGLab Pharma Co Ltd.

Provide Net Margin
for NewGLab Pharma Co Ltd.

Provide FCF Margin
for NewGLab Pharma Co Ltd.

Show all solvency ratios
for NewGLab Pharma Co Ltd.

Provide D/E Ratio
for NewGLab Pharma Co Ltd.

Provide D/A Ratio
for NewGLab Pharma Co Ltd.

Provide Interest Coverage Ratio
for NewGLab Pharma Co Ltd.

Provide Altman Z-Score Ratio
for NewGLab Pharma Co Ltd.

Provide Quick Ratio
for NewGLab Pharma Co Ltd.

Provide Current Ratio
for NewGLab Pharma Co Ltd.

Provide Cash Ratio
for NewGLab Pharma Co Ltd.

What is the historical Revenue growth
over the last 5 years for NewGLab Pharma Co Ltd?

What is the historical Net Income growth
over the last 5 years for NewGLab Pharma Co Ltd?

What is the current Free Cash Flow
of NewGLab Pharma Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for NewGLab Pharma Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
NewGLab Pharma Co Ltd

Current Assets 7.5B
Cash & Short-Term Investments 4.6B
Receivables 1.6B
Other Current Assets 1.2B
Non-Current Assets 9.8B
Long-Term Investments 4.3m
PP&E 4.8B
Intangibles 150.4m
Other Non-Current Assets 4.8B
Current Liabilities 38.1B
Accounts Payable 1B
Accrued Liabilities 3.1B
Short-Term Debt 1.3B
Other Current Liabilities 32.8B
Non-Current Liabilities -3.1B
Long-Term Debt 218m
Other Non-Current Liabilities -3.3B
Efficiency

Earnings Waterfall
NewGLab Pharma Co Ltd

Revenue
6.1B KRW
Cost of Revenue
-6.9B KRW
Gross Profit
-805.1m KRW
Operating Expenses
-11B KRW
Operating Income
-11.8B KRW
Other Expenses
12.1B KRW
Net Income
290.5m KRW

Free Cash Flow Analysis
NewGLab Pharma Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

NewGLab Pharma Co Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
ROE is Increasing
ROIC is Increasing
45/100
Profitability
Score

NewGLab Pharma Co Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

NewGLab Pharma Co Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
31/100
Solvency
Score

NewGLab Pharma Co Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
NewGLab Pharma Co Ltd

There are no price targets for NewGLab Pharma Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NewGLab Pharma Co Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for NewGLab Pharma Co Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one NewGLab Pharma Co Ltd stock?

The intrinsic value of one NewGLab Pharma Co Ltd stock under the Base Case scenario is 84.39 KRW.

Is NewGLab Pharma Co Ltd stock undervalued or overvalued?

Compared to the current market price of 6 915 KRW, NewGLab Pharma Co Ltd is Overvalued by 99%.

Back to Top